These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 12511681)

  • 1. First-pass MR imaging in the assessment of perfusion impairment in patients with hypertrophic cardiomyopathy and the Asp175Asn mutation of the alpha-tropomyosin gene.
    Sipola P; Lauerma K; Husso-Saastamoinen M; Kuikka JT; Vanninen E; Laitinen T; Manninen H; Niemi P; Peuhkurinen K; Jääskeläinen P; Laakso M; Kuusisto J; Aronen HJ
    Radiology; 2003 Jan; 226(1):129-37. PubMed ID: 12511681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cine MR imaging of myocardial contractile impairment in patients with hypertrophic cardiomyopathy attributable to Asp175Asn mutation in the alpha-tropomyosin gene.
    Sipola P; Lauerma K; Jääskeläinen P; Laakso M; Peuhkurinen K; Manninen H; Aronen HJ; Kuusisto J
    Radiology; 2005 Sep; 236(3):815-24. PubMed ID: 16014439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: a positron emission tomography study.
    Tuunanen H; Kuusisto J; Toikka J; Jääskeläinen P; Marjamäki P; Peuhkurinen K; Viljanen T; Sipola P; Stolen KQ; Hannukainen J; Nuutila P; Laakso M; Knuuti J
    J Nucl Cardiol; 2007; 14(3):354-65. PubMed ID: 17556170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The regional myocardial microvascular dysfunction differences in hypertrophic cardiomyopathy patients with or without left ventricular outflow tract obstruction: assessment with first-pass perfusion imaging using 3.0-T cardiac magnetic resonance.
    Xu HY; Yang ZG; Sun JY; Wen LY; Zhang G; Zhang S; Guo YK
    Eur J Radiol; 2014 Apr; 83(4):665-72. PubMed ID: 24521610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene.
    Magga J; Sipola P; Vuolteenaho O; Risteli J; Jääskeläinen P; Peuhkurinen K; Kuusisto J
    Am J Cardiol; 2008 Apr; 101(8):1185-90. PubMed ID: 18394456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac adrenergic activity is associated with left ventricular hypertrophy in genetically homogeneous subjects with hypertrophic cardiomyopathy.
    Sipola P; Vanninen E; Aronen HJ; Lauerma K; Simula S; Jääskeläinen P; Laakso M; Peuhkurinen K; Kuusisto J; Kuikka JT
    J Nucl Med; 2003 Apr; 44(4):487-93. PubMed ID: 12679389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of coronary microvascular dysfunction in hypertrophic cardiomyopathy: first-pass myocardial perfusion cardiovascular magnetic resonance imaging at 1.5 T.
    Huang L; Han R; Ai T; Sun Z; Bai Y; Cao Z; Morelli JN; Xia L
    Clin Radiol; 2013 Jul; 68(7):676-82. PubMed ID: 23566329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diastolic dysfunction without left ventricular hypertrophy is an early finding in children with hypertrophic cardiomyopathy-causing mutations in the beta-myosin heavy chain, alpha-tropomyosin, and myosin-binding protein C genes.
    Poutanen T; Tikanoja T; Jääskeläinen P; Jokinen E; Silvast A; Laakso M; Kuusisto J
    Am Heart J; 2006 Mar; 151(3):725.e1-725.e9. PubMed ID: 16504640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined first-pass perfusion and viability study at MR imaging in patients with non-ST segment-elevation acute coronary syndromes: feasibility study.
    Chiu CW; So NM; Lam WW; Chan KY; Sanderson JE
    Radiology; 2003 Mar; 226(3):717-22. PubMed ID: 12601212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging.
    Petersen SE; Jerosch-Herold M; Hudsmith LE; Robson MD; Francis JM; Doll HA; Selvanayagam JB; Neubauer S; Watkins H
    Circulation; 2007 May; 115(18):2418-25. PubMed ID: 17452610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation.
    Sipola P; Magga J; Husso M; Jääskeläinen P; Peuhkurinen K; Kuusisto J
    Eur Radiol; 2011 Jul; 21(7):1383-9. PubMed ID: 21274714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced global myocardial perfusion reserve in DCM and HCM patients assessed by CMR-based velocity-encoded coronary sinus flow measurements and first-pass perfusion imaging.
    Bietenbeck M; Florian A; Shomanova Z; Meier C; Yilmaz A
    Clin Res Cardiol; 2018 Nov; 107(11):1062-1070. PubMed ID: 29774406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducibility of life-threatening ventricular arrhythmias is related to maximum left ventricular thickness and clinical markers of sudden cardiac death in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene.
    Hedman A; Hartikainen J; Vanninen E; Laitinen T; Jääskeläinen P; Laakso M; Peuhkurinen K; Kuusisto J
    J Mol Cell Cardiol; 2004 Jan; 36(1):91-9. PubMed ID: 14734051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myocardial late gadolinium enhancement is associated with raised serum amino-terminal propeptide of type III collagen concentrations in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha tropomyosin gene: magnetic resonance imaging study.
    Sipola P; Peuhkurinen K; Lauerma K; Husso M; Jääskeläinen P; Laakso M; Aronen HJ; Risteli J; Kuusisto J
    Heart; 2006 Sep; 92(9):1321-2. PubMed ID: 16908707
    [No Abstract]   [Full Text] [Related]  

  • 15. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy.
    Matoh F; Satoh H; Shiraki K; Saitoh T; Urushida T; Katoh H; Takehara Y; Sakahara H; Hayashi H
    J Card Fail; 2007 Jun; 13(5):372-9. PubMed ID: 17602984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive determination of regional myocardial perfusion with first-pass magnetic resonance (MR) imaging.
    Nakajima T; Oriuchi N; Tsushima Y; Funabasama S; Aoki J; Endo K
    Acad Radiol; 2004 Jul; 11(7):802-8. PubMed ID: 15217598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-pass myocardial perfusion cardiovascular magnetic resonance at 3 Tesla.
    Su MY; Yang KC; Wu CC; Wu YW; Yu HY; Tseng RY; Tseng WY
    J Cardiovasc Magn Reson; 2007; 9(4):633-44. PubMed ID: 17578718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging measurement of left ventricular blood flow and coronary flow reserve in patients with chronic heart failure due to coronary artery disease.
    Aras A; Anik Y; Demirci A; Balci NC; Kozdag G; Ural D; Komsuoglu B
    Acta Radiol; 2007 Dec; 48(10):1092-1100. PubMed ID: 17963087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of left ventricular chamber stiffness at rest to exercise capacity in hypertrophic cardiomyopathy.
    Dumont CA; Monserrat L; Peteiro J; Soler R; Rodriguez E; Bouzas A; Fernández X; Pérez R; Bouzas B; Castro-Beiras A
    Am J Cardiol; 2007 May; 99(10):1454-7. PubMed ID: 17493479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations.
    Germans T; Wilde AA; Dijkmans PA; Chai W; Kamp O; Pinto YM; van Rossum AC
    J Am Coll Cardiol; 2006 Dec; 48(12):2518-23. PubMed ID: 17174192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.